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Abstract
The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety
of two different simeprevir (SMV) doses administered once-daily (QD) with pegylated interferon
(Peg-IFN)-α-2a and ribavirin (RBV) in treatment-naïve patients with HCV genotype 1 infection.
Patients were randomized to one of five treatments: SMV (75 or 150 mg QD) for 12 or 24 weeks
or placebo, plus Peg-IFN and RBV. Patients in the SMV arms stopped all treatment at week 24 if
response-guided therapy (RGT) criteria were met; patients not meeting RGT continued with Peg-
IFN and RBV until week 48, as did patients in the placebo control group. Sustained virologic
response (SVR) rates measured 24 weeks after the planned end of treatment (SVR24) were
74.7%-86.1% in the SMV groups versus 64.9% in the control group (P < 0.05 for all comparisons
[SMV versus placebo], except SMV 75 mg for 24 weeks). Rapid virologic response (HCV RNA
<25 IU/mL undetectable at week 4) was achieved by 68.0%-75.6% of SMV-treated and 5.2% of
placebo control patients. According to RGT criteria, 79.2%-86.1% of SMV-treated patients
completed treatment by week 24; 85.2%-95.6% of these subsequently achieved SVR24. The
adverse event profile was generally similar across the SMV and placebo control groups, with the
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exception of mild reversible hyperbilirubinemia, without serum aminotransferase abnormalities,
associated with higher doses of SMV.
Conclusion—SMV QD in combination with Peg-IFN and RBV significantly improves SVR
rates, compared with Peg-IFN and RBV alone, and allows the majority of patients to shorten their
therapy duration to 24 weeks.
The availability of direct-acting antiviral agents has recently transformed the treatment of
chronic hepatitis C (CHC).1,2 Triple-therapy regimens that include nonstructural protein
(NS)3/4A protease inhibitors, such as boceprevir and telaprevir, combined with pegylated
interferon (Peg-IFN) and ribavirin (RBV) significantly improve the rate of sustained
virologic response (SVR) for patients with genotype 1 CHC infection, compared with Peg-
IFN and RBV alone.3,4 Furthermore, many patients may qualify for a shortened duration of
therapy by incorporating a response-guided therapy (RGT) algorithm that determines the
duration of therapy according to on-treatment virologic response milestones.5
However, these regimens have also increased the complexity of treatment for patients and
amplified the adverse events (AEs) associated with hepatitis C therapy.6,7 Strict adherence
to three-times-daily dosing is required for boceprevir and telaprevir, along with
recommendations to be administered with food (with a specific fat content for telaprevir) to
enhance absorption of medications.6 Anemia is more frequent and severe when either of
these agents is used with Peg-IFN and RBV, whereas skin rash is more common with
telaprevir-containing regimens.3,4 Thus, effective treatments with simplified dosing
schedules and improved AE profiles would benefit patients with CHC.
Simeprevir (SMV; TMC435) is an oral, once-daily (QD), investigational hepatitis C virus
(HCV) NS3/4A macrocyclic protease inhibitor with potent antiviral activity in patients
infected with genotype 1 as well as antiviral activity demonstrated against isolates of
genotypes 2, 4, 5, and 6.8,9 In preclinical studies, the replicon half-maximal effective
concentration (EC50) for SMV ranged from 8 to 28 nM, and the liver-to-plasma
concentration ratio was high (ratio of 39).10 In a phase I study, patients with hepatitis C
genotype 1 treated with a 5-day course of SMV monotherapy exhibited a median maximal
reduction of HCV RNA of 3.9 log10, which compares favorably to that observed with
boceprevir (~2.45 log10 over 7 days) and telaprevir (~4.4 log10 over 14 days).8,11,12 Manns
et al. administered triple therapy with SMV (dose range: 25-200 mg QD) plus Peg-IFN-α-2a
and RBV in a phase IIa study for up to 28 days.13 The majority of patients, both treatment
naïve and treatment experienced, had HCV RNA below the lower level of quantification
(<25 IU/mL) of the HCV RNA assay by day 28 of therapy.13
The aim of the current study was to assess the efficacy and safety of two different doses of
SMV administered QD for two different durations in combination with Peg-IFN and RBV in
treatment-naïve patients infected with HCV genotype 1.
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Patients and Study Design
The Protease Inhibitor TMC435 study assessing optimaL dose and duration as once daiLy
Antiviral Regimen (PILLAR) study (NCT00882908; www.clinicaltrials.gov) was a phase
IIb, randomized, double-blind, placebo-controlled clinical trial designed to test the efficacy
and safety of SMV in combination with Peg-IFN and RBV, compared with Peg-IFN and
RBV alone, for the treatment of genotype 1 CHC. The study was performed in 13 countries
in North America, Europe, and Asia-Pacific regions. Enrollment began in May 2009, and the
study was completed in April 2011. The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki and was approved by the institutional review boards of
participating institutions. All patients provided written informed consent.
Adult patients with CHC were eligible for participation if they had plasma HCV RNA
>100,000 IU/mL, were infected with HCV genotype 1, had never received (Peg)IFN, RBV,
or other approved or investigational agents for chronic HCV infection, and were deemed
eligible to be treated with Peg-IFN-based regimens according to standard criteria.14 Patients
were excluded if they had cirrhosis on liver biopsy (required within 24 months of
enrollment), coinfection with human immunodeficiency virus or hepatitis B, platelet count
<90,000/mm3, or hemoglobin <12 g/dL for females and 13 g/dL for males.
Participants were randomly assigned in equal proportions, using a centralized, interactive
voice/web-response randomization system, to one of five treatment regimens with SMV at
doses of either 75 or 150 mg administered orally QD for 12 or 24 weeks or matched
placebo, in combination with Peg-IFN-α-2a 180 μg/week and RBV 1,000-1,200 mg/day
(Fig. 1). Participants who were randomized to 12 weeks of SMV therapy received an
additional 12 weeks of placebo plus Peg-IFN and RBV. Randomization was stratified by
hepatitis C genotype (1a, 1b, versus other) and by race (black, Caucasian, and other).
Patients receiving SMV were eligible for shortened treatment duration using an RGT
algorithm (all therapy completed at week 24 if HCV RNA <25 IU/mL at week 4 and
undetectable at weeks 12, 16, and 20). SMV-treated participants who did not meet these
virologic milestones continued therapy with Peg-IFN and RBV for up to 48 weeks. All
participants initially randomized to the placebo control arm were treated for up to 48 weeks;
RGT criteria were not applied (Fig. 1).
SMV/placebo was discontinued if viral breakthrough (VBT) occurred (confirmed increase in
plasma HCV RNA of >1 log10 IU/mL, compared with the lowest recorded on-treatment
value, or a confirmed plasma HCV RNA >100 IU/mL if previously below the level of
quantification [<25 IU/mL]). All medications were discontinued if there was a <2 log10
decline in HCV RNA, compared with baseline at week 12, or detectable HCV RNA at week
24 or 36. Investigators and participants were blinded to HCV RNA results through week 48
of treatment. An external physician monitored individual HCV RNA results and informed
investigators regarding protocol-directed treatment discontinuation.
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The primary outcome measure was the proportion of patients with HCV RNA <25 IU/mL
undetectable at week 72 (SVR W72; i.e., all patients assessed at the same time point
irrespective of treatment duration) in each of the SMV regimens, compared to placebo
control. Secondary measures included SVR at 12 and 24 weeks after planned end of
treatment (SVR12 and SVR24, respectively), comparisons of AEs and quality-of-life
measures between groups, an assessment of HCV NS3 sequence in patients not achieving
SVR, and an assessment of SMV pharmacokinetics. The influence of interleukin-28 (IL28)B
genotype on efficacy was explored in a subset of patients for whom genomic DNA was
available.
Assessments
Blood samples were taken at each study visit. Plasma HCV RNA was quantified using the
Roche COBAS TaqMan v2.0 assay (lower limit of quantification: 25 IU/mL; values below
this limit reported as HCV RNA <25 IU/mL detectable or undetectable; Roche Molecular
Diagnostics, Pleasanton, CA). HCV NS3/4A sequencing was also performed at baseline and
at relevant time points throughout the study, based on changes in plasma HCV RNA for
individual patients. AEs and laboratory data were recorded at each study visit. Patients
completed the Fatigue Severity Scale (FSS), a fatigue symptom and impact questionnaire,15
at baseline and weeks 0, 4, 12, 24, 36, 48, 60, and 72.
Statistical Analysis
Statistical analyses were performed by SGS Life Science Services (Geneva, Switzerland)
using SAS statistical software (version 9.1; SAS Institute Inc., Cary, NC).
Sample Size Determination and Analysis of Baseline Characteristics
Eighty patients were randomized to each treatment group, providing 77% power to detect a
difference of 25% in SVR24 rates between groups (70% for SMV groups and 45% for
placebo control). Sample-size calculation was based on SVR24 rates observed in previous
studies because, at the time of protocol writing, no reference SVR W72 rates were available.
Patient baseline demographics and disease characteristics were summarized descriptively.
Efficacy
SVR rates were compared between groups using a logistic regression model (closed testing
procedure), with factors baseline HCV RNA, race, and genotype subtype. Combined SMV
groups of the same dose (different duration) were first compared versus the control group
and, if significant, the two individual groups compared to control. The 95% confidence
intervals (CIs) were constructed around both the observed response rates and the differences
in rates between groups. Subgroup analyses, including application of a multivariate model,
were performed to assess correlation between baseline characteristics or early response
criteria and SVR.
Resistance Analysis
Population sequencing of the HCV NS3/4A region was conducted on samples collected at
baseline and time of treatment failure as previously described.16 The effect of the naturally
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occurring NS3 Q80K polymorphism, which confers low-level resistance to SMV (fold
change in EC50 value of 7.7 as a single amino acid substitution in a genotype 1b replicon)16
on SVR as well as the emergence of viral variants carrying NS3 amino acid substitutions in
patients not achieving SVR, were investigated.
Safety
Incidence of AEs and related parameters, clinical laboratory data, and vital-sign parameters
(actual values and changes from baseline) were summarized per study arm. Laboratory
abnormalities were determined according to the World Health Organization grading table
and in accord with the normal ranges of the clinical laboratory.
IL28B Genotype
IL28B genotype (locus rs1297860) was determined for a subset of patients who consented to
this analysis. Hardy-Weinberg’s equilibrium of the IL28B polymorphism was tested for the
study population, and the distribution of genotypes, according to baseline characteristics and
efficacy parameters, was summarized.
FSS
A total FSS score was calculated as the mean of nine items (range, 1-7), with higher scores
indicating increased fatigue. Area under the curve from baseline to week 72 was compared
between SMV and placebo control groups using a piecewise linear mixed model, with
treatment group and time as factors, and assuming data missing at random (Supporting
Document 1).
Results
Five hundred and six patients were screened for eligibility, of which 388 were randomized
to treatment. Two patients withdrew consent before therapy (one in an SMV group and one
in the placebo control group). Thus, a total of 386 patients, or 75-79 patients per treatment
arm, received at least one dose of study medication and are included in the intent-to-treat
analyses (Supporting Fig. A). Study completion rates were high; 92.5% of patients overall
completed the study, whereas 7.5% discontinued study participation prematurely.
Discontinuation of SMV and placebo and Peg-IFN and RBV occurred in 8.0%-15.6% of
SMV-treated patients and 13% of the control group (Supporting Table A) and occurred
because of AEs in 1.3%-5.2% in SMV groups and 5.2% in the control group.
Patient Characteristics
Demographics and baseline disease characteristics of participants within each treatment arm
are shown in Table 1. Most patients were Caucasian males with a median age of 46.5 years
and a body mass index (BMI) of 25.0 kg/m2. Approximately 68% of patients were enrolled
in Europe, 21% in North America, and 11% in Australia and New Zealand. HCV RNA
levels at baseline were greater than 800,000 IU/mL in over 80% of participants (between
81.8% and 91.1% in each treatment arm), and 50%-62% of patients were infected with HCV
genotype 1b. METAVIR stage F3 was present on pre-treatment liver biopsies in
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9.1%-22.7% of patients. The NS3 Q80K polymorphism was present at baseline in 10.4% of
patients (22.0% in HCV genotype 1a-and 1.0% in 1b-infected patients).
Virologic Response
The primary outcome measure, SVR W72, ranged between 70.7% and 84.8% for SMV
regimens, compared with 64.9% of those treated with Peg-IFN and RBV alone (Table 2).
The differences between SMV 150-mg groups and control were statistically significant (P <
0.05; Table 2). SVR24 was achieved in 74.7%-86.1% of those treated with SMV regimens,
compared to 64.9% of those treated with placebo. The differences in response rates between
SVR W72 and SVR24 were largely the result of missing HCV RNA data at week 72 from
participants who were lost to follow-up between those post-treatment time points. All
SVR24 comparisons between SMV treatment groups and placebo controls were statistically
significant (P < 0.05 or 0.005), except for SMV 75 mg for 24 weeks (Table 2).
Among patients treated with SMV, 68.0%-75.6% achieved rapid virologic response (RVR;
HCV RNA undetectable at week 4), of whom 87.9%-94.9% subsequently achieved SVR24.
Only 5.2% of placebo-treated patients had RVR. Based on RGT criteria, 79.2%-86.1% of
SMV-treated patients were eligible to complete treatment by week 24. SVR24 was
subsequently achieved in 85.2%-95.6% of these patients (Fig. 2).
Because no differences in SVR were noted between the 12- or 24-week durations of SMV,
the two SMV 75-mg dose groups and the two 150-mg groups were pooled for exploratory
subgroup analyses. For patients treated with SMV 75 mg, the SVR24 rates were lower for
genotype 1a, compared with genotype 1b (66.2% and 88.9%, respectively), although the
rates in genotype 1a and 1b patients were similar with SMV 150 mg (82.4% and 83.8%,
respectively). SVR rates for those treated with placebo were 66.7% for genotype 1a and
63.8% for genotype 1b.
Multivariate regression analysis was performed for factors associated with SVR, including
baseline HCV RNA level, METAVIR score (F3 versus F0-F2), genotype (1a versus 1b),
race (Caucasian versus black), and gender (Fig. 3). Treatment with SMV was associated
with higher rates of SVR for all of these factors. For patients with METAVIR scores of F0-
F2 (n = 332), SVR rates were 81.7% and 84.6% with SMV (75 and 150 mg, respectively)
and 64.3% with placebo control. For patients with scores of F3 (n = 53), rates were 63.0%
and 75.0% with SMV (75 and 150 mg, respectively), compared to 71.4% with placebo
control.
Among SMV-treated patients infected with HCV genotype 1a, those without a Q80K
polymorphism at baseline experienced higher SVR24 rates (SMV 150 mg: 53 of 62
[85.5%]; 75 mg: 36 of 51 [70.6%]), compared with patients with the Q80K polymorphism
(SMV 150 mg: 8 of 12 [66.7%]; 75 mg: 11 of 20 [55.0%]).
On-Treatment Failure and Relapse
In SMV treatment arms, the frequency of VBT was low, with 15 of 309 (4.9%) patients
experiencing VBT and, consequently, ceasing treatment with SMV (Table 2). VBT was
evenly distributed between the 75-mg (7 of 15) and 150-mg (8 of 15) arms, and each of
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these 15 patients subsequently met a stopping criterion at week 12 or 24, ending all
treatment. No additional SMV patients met stopping criteria. In contrast, 14.3% of those in
the placebo control group met stopping criteria at week 12, 24, or 36 and ceased all
treatment.
The majority of VBTs (9 of 15) occurred during the first 12 weeks of SMV dosing
(Supporting Table B), in line with previous reports. In SMV 12-week arms, 5 of 11
instances of VBT occurred after the end of SMV dosing; however, initial evidence of failure
emerged before week 12. VBT was more frequent among patients with genotype 1a,
compared with genotype 1b, although this difference was less apparent in the SMV 150-mg
dose group (6.8% and 3.8% with genotypes 1a and 1b, respectively).
Among patients who had undetectable HCV RNA at the end of treatment, viral relapse
occurred less frequently among those treated with SMV regimens than with placebo control
(11.8% versus 17.7%; Table 2). As with VBT, viral relapse was less common with the SMV
150-mg dose, particularly in HCV genotype 1a-infected patients, of whom 9% relapsed.
All 15 SMV-treated patients with sequence information available who experienced VBT and
27 of 33 (81.8%) with viral relapse had emerging mutations at NS3 amino acid positions 80,
155, and/or 168 at the time of VBT or relapse.
Differences in the type of emerging mutations were observed between genotype 1a- (mainly
emerging R155K alone or in combination with other mutations at NS3 positions 80 and/or
168) and 1b (mainly D168V)-infected patients. The majority (10 of 12; 83.3%) of patients
with baseline Q80K polymorphism experiencing VBT or relapse had emerging mutations
(mainly R155K) at time of failure.
IL28B Genotype and Response
Approximately two thirds of patients consented to IL28B genotype testing and, of these,
60%-78% had a non-CC IL28B genotype (Table 1). Among patients with non-CC
genotypes, rates of SVR24 were generally higher for patients treated with SMV 75 and 150
mg, compared to placebo control. SVR rates with SMV 75 mg were 83.9%, 78.1%, and
50.0%, and with SMV 150 mg were 97.1%, 80.0%, and 66.7% (CC, CT, and TT,
respectively). In contrast, in the placebo control group, SVR rates were 100% with CC and
50% with both CT and TT (Supporting Table D). VBT was observed exclusively in the non-
CC genotype (data not shown).
Safety
The most frequent AEs—fatigue, influenza-like illness, pruritus, headache, and nausea—
were those typically associated with Peg-IFN and RBV therapy and were similar across
SMV and placebo treatment groups (Table 3). AEs were the most common reason for
discontinuation of at least one study drug, ranging between 4% and 10.4% of participants
treated with SMV, compared to 13% in the placebo control group. Serious AEs (SAEs)
occurred with similar frequency among those treated with SMV (3.8%-11.5%) or placebo
control (13%). There were no deaths in the study.
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Anemia was reported as an AE in 19.0%-22.1% of patients treated with SMV (all grade 1-2)
and in 20.8% of those receiving placebo, and did not lead to discontinuation of SMV or
placebo (Table 3). The median maximal decrease in hemoglobin was similar for SMV and
placebo regimens (data not shown). Of note, the use of erythropoietin was not permitted
during the study. Skin rash of any type (considered by the investigator to be at least possibly
related to the study medication) was reported in 17.3%-30.8% of patients treated with SMV
and in 23.4% of those treated with placebo. Rash AEs led to discontinuation of SMV or
placebo in only 3 patients (2 in the SMV and 1 in the placebo control groups) occurred with
comparable frequency between SMV study arms, and the majority were grade 1-2 in
severity (Table 3).
A mild, isolated, and reversible increase in serum bilirubin was noted in patients treated with
SMV. Most elevations in bilirubin, both direct and indirect, were grade 1, and
hyperbilirubinemia led to discontinuation of SMV or placebo in only 1 patient (Table 3).
The mean increase in bilirubin was most pronounced in the SMV 150-mg dose groups.
Bilirubin decreased to baseline levels promptly after patients completed SMV dosing. Of
note, there were no concomitant increases in serum aspartate aminotransferase, alanine
aminotransferase (ALT), or alkaline phosphatase (ALP) associated with bilirubin elevations,
and most patients with increased serum amino-transferases at baseline elicited a biochemical
response during therapy (Fig. 4).
Patient-Reported Fatigue
Mean (± standard error) total FSS score increased from baseline (indicating more
debilitating fatigue) in a similar manner in all groups by week 24. Mean score then returned
to values comparable to baseline by week 36 and by week 60 in SMV and control groups,
respectively (Fig. 5). Results of the piecewise linear mixed model confirmed that fatigue
scores for patients receiving SMV were sig-nificantly lower, compared to placebo control
patients, over the 72-week study period (P < 0.001), likely resulting from the shorter mean
treatment duration in these groups.
Discussion
SMV administered QD in combination with Peg-IFN and RBV significantly improved rates
of SVR, compared with the Peg-IFN and RBV and placebo control groups. The study was
designed to evaluate two doses of SMV and two different durations of triple combination
therapy. Results from this study indicated that all four SMV treatment arms accomplished
similar rates of SVR, ranging between 75% and 86%, which were statistically significantly
higher than placebo control in all but one treatment group. Higher response rates were
observed with SMV 150 mg, compared with the 75-mg dose, in several patient subgroups,
including those infected with HCV genotype 1a. Importantly, the majority (79%-86%) of
patients treated with SMV were able to shorten the total duration of therapy to only 24
weeks. Of these patients, SVR rates of 93%-96% were observed among those who
completed 24 weeks of treatment with SMV 150 mg.
The current study was not powered to provide definitive data across subpopulations, and
observations must be confirmed in larger phase III trials. However, exploratory analyses of
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several subpopulations, some associated with lower response to Peg-IFN and RBV, such as
high levels of viremia at baseline and advanced fibrosis, indicated that triple therapy with
SMV provided benefit, compared to control. The influence of unfavorable IL28B genotype,
which is reported as being strongly associated with response to Peg-IFN and RBV,17-22 was
ameliorated by the addition of SMV. An increase in SVR24 was generally evident in SMV
treatment regimens, compared to placebo control, for non-CC genotypes. Whereas VBT was
infrequent, it was noted only among non-CC genotypes. For patients infected with HCV
genotype 1a, higher SVR rates were observed in patients without the Q80K polymorphism,
compared with those with the polymorphism. In the presence of Q80K, higher SVR rates
were noted with the 150-mg dose (the dose selected for ongoing phase III trials), compared
with the 75-mg dose. However, because the number of patients in the study with this
polymorphism was small (SMV 150 mg: n = 12; 75 mg: n = 21), no firm conclusions can be
drawn. The results of larger, ongoing phase III trials will allow further investigation of this
effect.
The magnitude of SVR in the control group treated with Peg-IFN and RBV alone was
unexpected, although not unprecedented.23,24 Progressively higher rates of SVR with Peg-
IFN and RBV have been noted as the importance of adherence has been recognized for
patients, and clinicians have become more adept at managing AEs. Adherence to treatment
is essential for optimization of SVR rates, and participation in well-controlled, prospective
clinical trials may increase adherence and, ultimately, SVR rates (17-21).17-21 The high rates
of treatment completion (over 90%) in the current study are consistent with this observation.
The exclusion of patients with cirrhosis and the enrollment of few black patients may have
also been contributing factors to the high SVR rate in the control group. However, no single
factor was identified in post-hoc analyses to explain the higher than anticipated response rate
in the control group. Nevertheless, statistical superiority of treatment with SMV-containing
regimens over Peg-IFN and RBV alone was established for all dose and duration regimens,
with the exception of SMV 75 mg administered for 24 weeks.
The high rates of SVR in SMV dosing groups were achieved without exacerbating the well-
defined safety pro-file of Peg-IFN and RBV. Treatment-emergent AEs among those
receiving SMV were generally similar to Peg-IFN and RBV alone. Specifically, there was
no increase in anemia, neutropenia, or adverse skin manifestations (rash and pruritus), in
contrast to the increased frequency of these side effects reported with currently available
triple-therapy regimens that include boceprevir or telaprevir.4,6 Hyperbilirubinemia, most
evident in the SMV 150-mg dosing arms, plateaued early during treatment, was not
progressive, and was rapidly reversible at the end of SMV dosing. There were no
concomitant increases in serum aminotransferases or ALP during the SMV dosing intervals,
further supporting the absence of hepatotoxicity. Studies in vitro have demonstrated that
SMV is an inhibitor of bilirubin transporters organic anion-transporting polypeptide 1B1 and
multidrug resistance-associated protein 2, suggesting a likely mechanism for
hyperbilirubinemia during SMV treatment.25
Incidence and severity of fatigue AEs were comparable for all treatment groups. Fatigue
severity measured using the FSS, a generic self-report fatigue measure that patients
completed during clinical visits throughout the study, clarified the relationship between
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treatment and fatigue. Fatigue severity increased comparably during therapy in all groups
and then returned to baseline when treatment ended; the shortened treatment duration
experienced by the majority of patients receiving SMV led to a reduced overall duration of
fatigue in those groups, without significantly increasing fatigue severity during treatment.
However, it should be noted that the exclusion of patients with cirrhosis (METAVIR score
F4) from this study precludes any firm conclusions from being made regarding the SMV
safety profile in patients with cirrhosis.
The ultimate aim of this phase IIb trial was to identify the optimal dose and duration of
SMV to be used for phase III registration trials. In the current study, there were no
substantial differences across SMV treatment regimens in the proportion of patients
qualifying for RGT, achieving SVR, or in safety analyses, with which to select the dose for
phase III studies. Thus, other, more subtle information derived from this study informed
dosing decisions for the phase III trials. First, results indicate that a 12-week treatment
duration is most appropriate. VBT, although uncommon in patients treated with SMV, was
usually evident within the first 12 weeks of therapy and viral relapse rates were similar
between the 12- and 24-week groups, suggesting that extending SMV to 24 weeks would not
provide additional benefit. Second, data support the selection of the SMV 150-mg dose. In
the SMV 150-mg dose group, higher SVR and lower viral relapse rates were observed with
the 1a genotype, compared to the 75-mg groups. Response rates in patients with IL28B non-
CC genotypes were also slightly higher with 150 mg, compared with 75 mg. Furthermore, in
patients infected with HCV genotype 1a, higher response rates were observed with the SMV
150-mg group (compared with 75 mg) in patients with higher BMI as well as in those with
METAVIR F3 scores. Thus, SMV 150 mg administered QD for 12 weeks in combination
with Peg-IFN and RBV, followed by Peg-IFN and RBV for an additional 12 weeks in an
RGT algorithm, was selected for ongoing phase III trials in treatment-naïve and -
experienced populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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BMI body mass index
CHC chronic hepatitis C
CI confidence interval
EC50 half-maximal effective concentration
FSS Fatigue Severity Scale




PILLAR The Protease Inhibitor TMC435 study assessing optimaL dose and duration




RVR rapid virologic response
SAE serious adverse event
SMV simeprevir
SVR sustained virologic response
SVR12 SVR 12 weeks after the planned end of treatment
SVR24 SVR 24 weeks after the planned end of treatment
SVR W72 SVR at week 72
VBT viral breakthrough
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FU, follow-up; PegIFN/RBV, peginterferonα-2a (180 μg/wk) + ribavirin (1000-1200 mg/
day); RGT, response-guided therapy; SMV, simeprevir; W, weeks.
Fried et al. Page 14























Rates of SVR for the ITT population and for patients who met virologic criteria for
shortened duration of therapy.
ITT, intent-to-treat; PegIFN/RBV, peginterferon α-2a + ribavirin; RGT, response-guided
therapy; SMV, simeprevir; SVR24, sustained virologic response (HCV RNA <25 IU/ml
undetectable) 24 weeks after planned end of treatment; W, week.
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Difference in SVR24 between SMV 150 mg and placebo groups by demographic
parameters.
CI, confidence interval; PegIFN/RBV, peginterferon α-2a + ribavirin; SMV, simeprevir;
SVR24, sustained virologic response (HCV RNA <25 IU/mL undetectable 24 weeks after
planned end of treatment.
†Patients with cirrhosis were not eligible.
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Change in bilirubin and ALT concentration up to week 72.
ALT, alanine aminotransferase; PegIFN/RBV, peginterferonα-2a + ribavirin; SE, standard
error; SMV, simeprevir.
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Change from baseline in total FSS score up to week 72.
FSS, Fatigue Severity Scale; PegIFN/RBV, peginterferon α-2a and ribavirin; SE, standard
error; SMV, simeprevir; W, week.
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